Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck

Retrospective Study of Effect of Accelerated Radiation Therapy , Six Fractions Per Week , for Squamous Cell Carcinoma of Head and Neck.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05291663

Enrollment

100

Registered

2022-03-23

Start date

2022-03-20

Completion date

2023-12-20

Last updated

2022-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Squamous Cell Carcinoma

Brief summary

Evaluation of the efficacy of the accelerated radiotherapy in squamous cell carcinoma of head and neck

Detailed description

* HNSCC is the sixth most common cancer worldwide, with 890.000 new cases and 450.000 deaths in 2018. * The incidence of HNSCC continues to rise and is anticipated to increase by 30% (that is, 1.08 million new cases annually) by 2030. * Squamous cell carcinoma constitutes 90% of all head and neck cancers and it predominates in males. * Risk factors such as cigarette consumption and alcohol consumption, are well established. * Treatment decisions are guided by clinic-pathologic factors such as age and stage. * Treatment of the majority of patients with HNSCC requires multimodality approaches. * Radiotherapy or surgery alone can be considered as the standard treatment modality for patients having early head and neck squamous cell carcinoma. * When conventionally fractionated radiotherapy is used, long-term tumor control can be achieved in less than 30% of patients with advanced head and neck carcinomas.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

* Patients of (18 up to 75 years of age) * Performance status of 0-2 according to ECOG scale. * Patients with no prior chemotherapy, radiotherapy or surgery except for biopsy.

Exclusion criteria

* Patients with previous irradiation to head and neck. * Pregnant or lactating women. * Patients with impaired heart or lung diseases.

Design outcomes

Primary

Measure	Time frame	Description
Determine progression-free survival rate	Baseline	Determine the toxicity and loco-regional control by using accelerated RTH in squamous cell carcinoma in head and neck

Contacts

Primary ContactZienab Kamel

zienab95kamel@gmail.com+201022997677

Backup ContactMostafa El-sayed Abd Elwanis

Mostafa.wanis@aun.edu.eg+201221133032

Outcome results